Use of canakinumab in the cryopyrin-associated periodic syndrome

New England Journal of Medicine

Volumn 360, Issue 23, 2009, Pages 2416-2425

  Lachmann, Helen J ^a   Kone Paut, Isabelle ^b   Kuemmerle Deschner, Jasmin B ^d   Leslie, Kieron S ^e   Hachulla, Eric ^f   Quartier, Pierre ^c   Gitton, Xavier ^g   Widmer, Albert ^g   Patel, Neha ^g   Hawkins, Philip N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIV LILLE   (France)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACZ 885; C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 1BETA ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOINFLAMMATORY DISEASE; BRONCHITIS; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CRYOPYRIN ASSOCIATED PERIODIC SYNDROME; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GENETIC ASSOCIATION; HUMAN; IMMUNOGENICITY; INFECTION RATE; INFLAMMATORY DISEASE; INFLUENZA; INJECTION SITE REACTION; MALE; MULTICENTER STUDY; NAUSEA; PATIENT SATISFACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; REPEATED DRUG DOSE; RHINITIS; RHINOPHARYNGITIS; SCHOOL CHILD; SIDE EFFECT; SPRAIN; THERAPY EFFECT; THRUSH; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; UROSEPSIS; VERTIGO; VIRUS INFECTION; WEIGHT GAIN;

EID: 66649102432     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0810787     Document Type: Article

References (20)

1. Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredofamilial syndrome. Q J Med 1962;31:235-248
2. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-612 (Pubitemid 38198844)
3. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007;356:2361-2371 (Pubitemid 46883770)
4. Church LD, Cook GP, McDermott MF. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol 2008;4:34-42.
5. Dinarello CA. The many worlds of reducing interleukin-1. Arthritis Rheum 2005;52:1960-1967 (Pubitemid 40994316)
6. Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 2008;47:309-310
7. Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-1597 (Pubitemid 44969215)
8. Ross JB, Finlayson LA, Klotz PJ, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008;12:8-16.
9. Yamazaki T, Masumoto J, Agematsu K, et al. Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome. Arthritis Rheum 2008;58:864-868
10. Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-2452
11. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008;10:R67.
12. Lachmann HJ, Jung T, Felix SD, et al. Treatment of cryopyrin associated periodic fever syndrome with a fully human anti-IL-1beta monoclonal antibody (ACZ885): results from a subcutaneous administration study. Clin Exp Rheumatol 2008;26:181.
13. Kuemmerle-Deschner JB, Tzaribachev N, Hansmann S, et al. Long-lasting response to ACZ885 (a new human IgG1 anti-IL-1β monoclonal antibody) in patients with Muckle-Wells Syndrome (MWS). Clin Exp Rheumatol 2008;26:180.
14. Kummerle-Deschner J, Tzaribachev N, Hansmann S, et al. Long lasting response to ACZ885 in patients with Muckle-Wells-Syndrome (MWS). Ann Rheum Dis 2008;67:Suppl II:104.
15. Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin-1beta in patients with cryopyrin associated periodic syndromes. J Exp Med 2009 April 13 (Epub ahead of print).
16. Temple RJ. Special study designs: early escape, enrichment, studies in non-responders. Commun Stat 1994;23:499-531.
17. Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis. Expert Opin Investig Drugs 2008;17:349-359
18. Karanikolas G, Charalambopoulos D, Vaiopoulos G, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. Rheumatology (Oxford) 2008;47:1384-1388
19. Maier J, Birkenfeld G, Pfirstinger J, Schölmerich J, Fleck M, Brühl H. Effective treatment of steroid refractory adult-onset Still's disease with anakinra. J Rheumatol 2008;35:939-941
20. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64:Suppl 4:iv2-iv14. (Pubitemid 41532009)